Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1098 details
Primary information
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesBone Density Conservation Agents
Patents NumberUS6440392
Date of Issue02/02/01
Date of Expiry02/02/21
Drug InteractionEskalith (lithium)
TargetCalcitonin receptor
Information of corresponding available drug in the market
Brand NameCalcimar
CompanyN.A.
Brand DiscriptionCalcitonin is a group of polypeptide hormones secreted by the thyroid gland in mammals and by the ultimobranchial gland of birds and fish. It is of physiological importance in the regulation of calcium metabolism in certain animal species, and may also ha
Prescribed forTo treat Paget's disease of bone
Chemical NameN.A.
FormulationEach mL of sterile solution contains calcitonin salmon 200 IU. Nonmedicinal ingredients include acetic acid, phenol, sodium acetate, sodium chloride, sodium hydroxide and water for injection.
Physcial AppearnceSolution
Route of AdministrationSubcutaneous or intramuSubcutaneousular Injection
Recommended DosageBased on body weight and injected every 12 hours
ContraindicationAllergy
Side EffectsFeeling light-headed, fainting; or muscle stiffness.
Useful Linkhttp://www.drugs.com/sfx/calcimar-side-effects.html
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)